| 引用本文:艾艳珂1，刘佳1，赵天易1，孟祥然1，曹雪1，王世华1，李姗珊1，李少红1，吕晓颖1，李洪皎1，孙海舒2，李杨3，赵贺4，何丽云1，雒琳1.基于前瞻性队列的登记研究评价上市后经典名方治疗结局的设计要点思考——以安宫牛黄丸治疗急性缺血性脑卒中为例[J].世界中医药,2022,(05):. |
|
| 基于前瞻性队列的登记研究评价上市后经典名方治疗结局的设计要点思考——以安宫牛黄丸治疗急性缺血性脑卒中为例 |
| Key Points in the Design of Registry-based Prospective Cohort Study to Evaluate the Outcome of Post-marketing Classical Chinese Patent Medicines——Taking Angong Niuhuang Pills for Acute Ischemic Stroke as an Example |
| 投稿时间：2022-01-10 |
| DOI：10.3969/j.issn.1673-7202.2022.05.002 |
| 中文关键词: 登记研究 前瞻性队列研究 治疗结局评估 上市后经典名方 研究设计 |
| English Keywords:Registry study Prospective cohort study Treatment outcome evaluation Post-marketing classical Chinese patent medicines Study design |
| 基金项目:国家重点研发计划项目“中医药现代化研究”重点专项（2017YFC1703600）；中国中医科学院科技创新工程项目（CI2021A00702-02） |
|
| 摘要点击次数: 469 |
| 全文下载次数: 0 |
| 中文摘要: |
| 中医上市后经典名方虽然在国内被广泛应用，但缺乏高质量的循证证据支撑，影响其走出国门。设计良好的基于前瞻性队列的登记研究可更加真实地反映上市后经典名方在现实医疗环境下治疗与结局的因果效应关系。本文以安宫牛黄丸治疗急性缺血性脑卒中为例，从控制选择性偏倚、信息偏倚和混杂偏倚的角度，在临床设计、统计学考量和质量控制3个方面对基于前瞻性队列的登记研究设计要点进行论述。 |
| English Summary: |
| Post-marketing classical Chinese patent medicines(CPMs) have been widely used in China.However，lack of high-quality evidence-based data blocks its promoting abroad.A well-designed registry-based prospective cohort study can help better understand the causal relationship between treatment and outcome in a realistic medical environment.In this paper，we took Angong Niuhuang Pills for the treatment of acute ischemic stroke as an example to discuss the key points in clinical design，statistical considerations，and quality control in the design of registry-based cohort study from the perspective of controlling selection bias，information bias，and confounding bias. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
